Royalty Pharma RPRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.72M— | —— | —— | —— | $13.4M— | ||
| $718.23M-13.2% | $827.15M+17.7% | $702.62M+93.0% | $363.98M-38.9% | $596.08M-19.7% | ||
| $4.32M+50.0% | $2.88M0.0% | $2.88M0.0% | $2.88M-77.1% | $12.59M0.0% | ||
| $452.37M-38.3% | $733.69M-23.7% | $961.87M+86,244% | $1.11M+5.4% | $1.06M-99.8% | ||
| -$477.87M+43.6% | -$847.8M+11.5% | -$958.31M-207% | -$311.98M-162% | $503.92M+200% | ||
| $50.1M-37.8% | $80.54M-45.0% | $146.49M-49.8% | $291.57M-58.9% | $708.78M+1,247% | ||
| $39.88M-2.1% | $40.76M+18.9% | $34.28M-11.2% | $38.61M-28.3% | $53.83M+71.2% | ||
| -$226K+87.4% | -$1.79M— | $0— | $0— | $0+100% | ||
| -$272.67M+9.0% | -$299.6M— | —— | -$507.81M+46.1% | -$941.3M— | ||
| -$32.3M+89.9% | -$320.25M-204% | $307.04M+167% | -$455.81M-387% | $158.69M— | ||
| $173.53M+2,497% | $6.68M-94.9% | $129.99M+16,231% | $796K-99.4% | $138.82M+17,145% | ||
| $3.72M— | —— | —— | —— | $13.4M— | ||
| $25.5M-49.5% | $50.5M— | —— | —— | $50.5M+10,000% | ||
| $9.7M+6.8% | $9.08M+435% | $1.7M+880% | $173K— | $0— | ||
| $36.25M-37.8% | $58.24M+70.4% | $34.18M-63.7% | $94.03M-7.5% | $101.7M+40.4% | ||
| $33.62M+15.5% | $29.1M0.0% | $29.11M+21.0% | $24.05M-24.3% | $31.76M+7.6% | ||
| $915.6M-0.1% | $916.13M+3.8% | $882.36M+21.4% | $726.53M-12.4% | $829.74M+6.7% | ||
| $3.77M+9,574% | $39K-85.2% | $264K+10.0% | $240K+35.6% | $177K-22.0% | ||
| $50M+1,743% | $2.71M— | $0-100% | $218.6M+337% | $50M+100% | ||
| $22.5M-58.3% | $54M— | —— | —— | $4.43M— | ||
| $375K-98.9% | $34.72M— | $0— | $0— | $0-100% | ||
| $0— | —— | —— | —— | $510.55M— | ||
| $4.32M+50.0% | $2.88M0.0% | $2.88M0.0% | $2.88M-77.1% | $12.59M0.0% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $104.49M+10.8% | $94.34M-1.0% | $95.31M+2.2% | $93.24M-2.2% | $95.36M+1.8% | ||
| $39.88M-2.1% | $40.76M+18.9% | $34.28M-11.2% | $38.61M-28.3% | $53.83M+71.2% | ||
| $77.97M-1.5% | $79.15M-22.3% | $101.91M+14.2% | $89.22M+5.4% | $84.63M+4.2% | ||
| $0— | $0-100% | $15K-99.7% | $4.61M+328% | $1.08M+4.5% | ||
| $0— | —— | —— | $219K-0.5% | $220K0.0% | ||
| -$226K+87.4% | -$1.79M— | $0— | $0— | $0+100% | ||
| $6.5M+1.9% | $6.37M-12.1% | $7.25M-16.3% | $8.66M-28.0% | $12.03M+33.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Royalty Pharma generate?
- Royalty Pharma (RPRX) generated $2.6B in operating cash flow over the trailing twelve months.
- Where does Royalty Pharma's cash flow data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
